Literature DB >> 18023574

Molecular heterogeneity of colorectal cancer: Implications for cancer control.

Jeremy R Jass1.   

Abstract

Colorectal cancer (CRC) is a multi-pathway disease. A molecular approach to the classification of CRC utilises: (1) the type of genetic instability, specifically microsatellite instability (MSI) versus stable (MSS), and (2) the presence of DNA methylation or the CpG island methylator phenotype (CIMP). The MSS/CIMP-neg subset evolves through the classical adenoma-carcinoma sequence while the MSI/CIMP-pos and MSS/CIMP-pos subsets evolve through the recently recognised 'serrated pathway'. This review will show that the existence of two or more independent pathways to CRC is relevant to cancer prevention. In particular, new strategies for detecting and managing sessile serrated polyps will need to be developed and evaluated.

Entities:  

Mesh:

Year:  2007        PMID: 18023574     DOI: 10.1016/j.suronc.2007.10.039

Source DB:  PubMed          Journal:  Surg Oncol        ISSN: 0960-7404            Impact factor:   3.279


  43 in total

1.  Clinical meaning of BRAF mutation in Korean patients with advanced colorectal cancer.

Authors:  Bun Kim; Soo Jung Park; Jae Hee Cheon; Tae Il Kim; Won Ho Kim; Sung Pil Hong
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

2.  The miRNA landscape of colorectal polyps.

Authors:  Martha L Slattery; Jennifer S Herrick; Roger K Wolff; Lila E Mullany; John R Stevens; Wade Samowitz
Journal:  Genes Chromosomes Cancer       Date:  2017-02-01       Impact factor: 5.006

3.  Prediagnostic Physical Activity and Colorectal Cancer Survival: Overall and Stratified by Tumor Characteristics.

Authors:  Sheetal Hardikar; Polly A Newcomb; Peter T Campbell; Aung Ko Win; Noralane M Lindor; Daniel D Buchanan; Karen W Makar; Mark A Jenkins; John D Potter; Amanda I Phipps
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-05-14       Impact factor: 4.254

4.  Genetic biomarkers for neoplastic colorectal cancer in peripheral lymphocytes.

Authors:  Mirela Ionescu; Mihai Ciocirlan; Cristina Ionescu; Gabriel Becheanu; Serban Gologan; Adriana Teiusanu; Tudor Arbanas; Diculescu Mircea
Journal:  Maedica (Buchar)       Date:  2011-04

5.  Promoter methylation status of hMLH1, hMSH2, and MGMT genes in colorectal cancer associated with adenoma-carcinoma sequence.

Authors:  Kyung-Hwa Lee; Ji-Shin Lee; Jong-Hee Nam; Chan Choi; Min-Cheol Lee; Chang-Soo Park; Sang-Woo Juhng; Jae-Hyuk Lee
Journal:  Langenbecks Arch Surg       Date:  2011-06-25       Impact factor: 3.445

6.  Differences in epidemiologic risk factors for colorectal adenomas and serrated polyps by lesion severity and anatomical site.

Authors:  Andrea N Burnett-Hartman; Michael N Passarelli; Scott V Adams; Melissa P Upton; Lee-Ching Zhu; John D Potter; Polly A Newcomb
Journal:  Am J Epidemiol       Date:  2013-03-03       Impact factor: 4.897

7.  Gender modifies the effect of ursodeoxycholic acid in a randomized controlled trial in colorectal adenoma patients.

Authors:  Patricia A Thompson; Betsy C Wertheim; Denise J Roe; Erin L Ashbeck; Elizabeth T Jacobs; Peter Lance; María Elena Martínez; David S Alberts
Journal:  Cancer Prev Res (Phila)       Date:  2009-12-01

8.  Genomic aberrations occurring in subsets of serrated colorectal lesions but not conventional adenomas.

Authors:  Andrea N Burnett-Hartman; Polly A Newcomb; John D Potter; Michael N Passarelli; Amanda I Phipps; Michelle A Wurscher; William M Grady; Lee-Ching Zhu; Melissa P Upton; Karen W Makar
Journal:  Cancer Res       Date:  2013-03-28       Impact factor: 12.701

9.  Cryopreservation of human colorectal carcinomas prior to xenografting.

Authors:  Michael Linnebacher; Claudia Maletzki; Christiane Ostwald; Ulrike Klier; Mathias Krohn; Ernst Klar; Friedrich Prall
Journal:  BMC Cancer       Date:  2010-07-08       Impact factor: 4.430

10.  Time from positive screening fecal occult blood test to colonoscopy and risk of neoplasia.

Authors:  Ziad F Gellad; Daniel Almirall; Dawn Provenzale; Deborah A Fisher
Journal:  Dig Dis Sci       Date:  2008-12-18       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.